Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – What’s Next?

Structure Therapeutics Inc. (NASDAQ:GPCR)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $21.05, but opened at $21.68. Structure Therapeutics shares last traded at $20.36, with a volume of 67,221 shares changing hands.

Analyst Ratings Changes

A number of equities research analysts have commented on GPCR shares. William Blair started coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reiterated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, Stifel Nicolaus started coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Stock Performance

The stock’s fifty day simple moving average is $24.48 and its 200-day simple moving average is $31.43. The stock has a market cap of $1.15 billion, a P/E ratio of -27.03 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. As a group, equities research analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its stake in shares of Structure Therapeutics by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after purchasing an additional 221,851 shares during the last quarter. FMR LLC boosted its position in Structure Therapeutics by 6.7% during the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock valued at $268,977,000 after acquiring an additional 383,635 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Structure Therapeutics by 5.1% during the 4th quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company’s stock worth $112,816,000 after acquiring an additional 203,010 shares during the period. Deep Track Capital LP increased its holdings in Structure Therapeutics by 129.4% in the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock worth $75,936,000 after purchasing an additional 1,579,492 shares in the last quarter. Finally, Vestal Point Capital LP increased its position in Structure Therapeutics by 50.0% in the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after buying an additional 575,000 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.